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Abstract 
 Erdheim-Chester disease is a rare inflammatory condition characterized by a non-
Langerhans’ histiocytic infiltration, involving the skeleton, nervous system, viscera, 
retroperitoneum, and elsewhere.  The aetiology is unknown. Positron-emission tomography 
shows areas of involvement. We managed a dialysis patient with knee pain; a bone marrow 
specimen showed typical CD68 positive, but CD1a negative cells. We initiated interferon-α 
therapy although other options remain open. In our patient, the simultaneous presence of 
secondary hyperparathyroidism with tumorous calcifications provided an interesting 
additional differential diagnostic possibility regarding skeletal pain. 
 
Introduction 
 Bone pain in poorly controlled dialysis patients with secondary hyperparathyroidism 
and chronic hyperphosphatemia suggests the presence of parathyroid hormone-initiated 
osteitis fibrosa cystica. When tumorous metastatic calcifications are discovered matters seem 
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clear. Our investigations uncovered a rare disease that had been overlooked. As a result, we 
were introduced to the multifaceted clinical presentations of non-Langerhans cell 
histiocytosis, Erdheim-Chester disease (ECD) [1]. 
 
Case report 
 The 45 year-old continuous-ambulatory peritoneal dialysis patient was admitted 
because of generalized progressive weakness, lassitude, bilateral knee pain, and an elevated 
C-reactive protein (CRP). She was a recovered heroin addict receiving methadone and had 
been treated successfully for hepatitis C virus. She had undergone renal biopsy for diminished 
renal function and proteinuria earlier, which revealed arteriolosclerosis and focal-sclerosing 
glomerulosclerosis. Dialysis commenced 3 years prior to admission. The patient’s compliance 
to this treatment was suboptimal. She also reported that 7 years earlier she had undergone 
bone-marrow aspiration for unexplained anaemia and that a non-Langerhans cell (CD1a 
negative, CD68 positive) histiocytosis had been diagnosed. We were unable to obtain further 
medical records concerning that episode. The patient had observed a 3 kg weight loss, as well 
as a decrease in her daily urinary output. She was normotensive (130/90 mm Hg), had a 
regular pulse, clear lungs, a systolic murmur consistent with mitral regurgitation, no 
organomegaly, and moderate pedal oedema. A moveable infraclavicular 2-cm diameter mass 
was palpated. Routine laboratory values were unremarkable, save for a CRP 139 mg/dL, 
parathyroid hormone 275 ng/L, calcium 2.48 mmol/L and elevated phosphorus 2.87 mmol/L. 
 Roentgenogram of both knees revealed bilateral 3 cm soft-tissue calcifications, medial 
to the knee joints. Joint space was preserved and unremarkable (Figure 1A), while the hand 
films showed no evidence of hyperparathyroidism. We performed a biopsy of the 
subclavicular mass and found metastatic calcification, without histiocytic infiltration (not 
shown). We diagnosed tumorous soft-tissue calcifications (Figure 1A and 1B) related to 
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poorly controlled secondary parathyroidism and in the course of the hospitalization a 5/6 
parathyroidectomy was performed [2]. Nonetheless, the nontypical knee pain that persisted 
and the history of histiocytosis puzzled us. A recent report in nephrology journal led us to 
conclude that Occam’s razor is not always all that sharp [3]. The report concerns a woman 
with knee pain, polyuria, and bilateral hydronephrosis. Imaging of the knees and long bones 
in that patient showed diffuse irregular sclerotic changes involving the long bones. The 
hydronephrosis was caused by collagenous fibro-adipose tissue with lymphoplasma cells and 
histiocytic infiltration. The histiocytes were CD1a negative, but CD68 positive. We 
recognized the condition as ECD, a non-Langerhans cell histiocytosis.  
 Additional imaging of our patient revealed sclerotic changes of both proximal and 
distal femurs bilaterally (Figure 2A), whereas additional tumorous calcifications are also 
visible. We performed whole-body positron-emission tomography (CT-PET) scanning with 
18F deoxyglucose (Figure 2B). The study revealed osteolytic and osteoplastic changes with 
increased activity at numerous sites including proximal and distal long bones, clavicles, 
sacrum, acetabula and glenoids. Note was also made of tumorous calcifications at various 
sites. We performed a bone-marrow biopsy (Figure 3A). That study showed, in addition to 
changes of secondary hyperparathyroidism (not shown) intense infiltration with lipid-laden 
histiocytic cells. The cells were CD1a negative, but CD68 positive (Figure 3B). Long-term 
high-dose interferon-α is considered a treatment of choice for ECD and was initiated by our 
consultants [4]. We are currently observing our patient, who seems to be improving.  
 
Discussion 
 ECD is a rare non-Langerhans cell histiocytosis characterized by infiltration of foamy 
CD68 positive, but CD1a negative macrophages and fibro-inflammatory lesions in various 
- 4 - 
organs, including retroperitoneal sites, periureteral areas, as recently reported by Kang et al 
[3], and bones. The origin and pathophysiology, of ECD are unknown. Cavalli et al [1] 
recently reviewed the topic and identified 259 ECD patients. They predominantly presented 
with skeletal symptoms, diabetes insipidus, neurological, and constitutional manifestations. 
The authors observed that ECD presented most frequently with skeletal symptoms. Bone 
involvement, both silent and symptomatic, was present in almost all patients. 
Roentgenographic findings were commonly symmetric diaphyseal osteosclerosis with 
contrast-material uptake in long bones by scintigraphy, as we observed in our PET-CT 
studies. The histology invariably showed a xanthogranulomatous infiltrate composed by 
foamy histiocytes accompanied by fibrosis. Immunohistochemical studies revealed that the 
infiltrating histiocytes were positive for CD68, but negative for the dendritic cell markers 
CD1a. 
 Cavalli et al [1] also emphasized that constitutional symptoms represented the initial 
complaint of ECD patients in 20% of cases, as was the case here. Our patient’s CRP has since 
decreased. Although an interferon-α therapy has been favoured [4], other options are 
available. Aubert et al [5] reported a refractory ECD patient who was given the interleukin-1 
receptor antagonist, anakinra. After 1 year of treatment, the CT-PET studies revealed an 
outstanding response of the skeletal involvement with clearly lower and smaller hyper-
metabolism images in that patient. Should interferon-α and anakinra fail, we were interested 
to learn about another feature of ECD that could also have mechanistic implications. Haroche 
et al [6] reported on a dramatic efficacy of vemurafenib in three refractory ECD patients. 
Vemurafenib has been employed in the treatment of patients with malignant melanoma, 
whose tumours feature BRAF V600E mutations. BRAF encodes the protein B-Raf, a 
serine/threonine-protein kinase.  Vemurafenib is approved for treatment of late-stage 
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melanoma with the V600E mutation. Haroche et al [6] point out that 57% of patients with 
Langerhans cell histiocytosis and 54% of ECD patients harbour the BRAF V600E mutation in 
their aberrant histiocytes. Should our patient not respond to our current therapy, we would 
perform genotyping for V600E. 
 William of Ockham was an English Franciscan friar, scholastic philosopher, and 
theologian. His idea, termed “Occam’s razor” states that when explaining a phenomenon one 
should always opt for the fewest possible causes, factors, or variables, preferably only one. 
We initially assumed that secondary hyperparathyroidism explained our patient’s pain. 
Sometimes clinicians must veer from Occam’s path and accept the possibility that both “lice 
and fleas” are present. Neither do we believe that tumorous calcifications and ECD are 
associated. Nor do we have any evidence that ECD participated in our patient’s chronic renal 
failure. 
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Figure 1. Roentgenograms of both knees (1A). Striking are the medial tumorous calcifications 
adjacent to the knee joints bilaterally. No changes consistent with calcium pyrophosphosphate 
deposition could be found. (1B). Computerized positron emission tomography (PET-CT) with 
contrast of knee joints. Markedly enhanced glucose metabolism localized to soft-tissue 
excrescences medial to both knees, although enhancement is also evident in the proximal tibia 
bilaterally. 
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Figure 2 A. Sclerosis of both distal and proximal femurs is evident. Note is also made of the 
tumorous soft-tissue calcification adjacent to both trochanters and at other sites. Figure 2B. 
Total-body PET-CT shows markedly increased glucose metabolism at numerous skeletal 
sites, particularly proximal and distal long bones and pelvis. 
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Figure 3A. Bone marrow biopsy shows marked infiltration by lipid-laden cells. Figure 3B. 
The cells stained for CD68 (brown coloration), but not for CD1a.  
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